Donafenib

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206144

CAS#: 1130115-44-4

Description: Donafenib, also known as CM-4307, is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).


Price and Availability

Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
Size
Price

50mg
Not available
500mg
Not available
5g
Ask price

Donafenib is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 206144
Name: Donafenib
CAS#: 1130115-44-4
Chemical Formula: C21H13D3ClF3N4O3
Exact Mass: 467.1051
Molecular Weight: 467.8475
Elemental Analysis: C, 53.91; H, 4.09; Cl, 7.58; F, 12.18; N, 11.98; O, 10.26


Synonym: Donafenib; CM-4307; CM 4307; CM4307.

IUPAC/Chemical Name: 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-2-pyridinecarboxamide

InChi Key: MLDQJTXFUGDVEO-FIBGUPNXSA-N

InChi Code: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3

SMILES Code: O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C=C2)=C1)NC([2H])([2H])[2H]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Ho V, Lim TS, Lee J, Steinberg J, Szmyd R, Tham M, Yaligar J, Kaldis P, Abastado JP, Chew V. TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget. 2015 Jul 23. [Epub ahead of print] PubMed PMID: 26287667.

2: Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer. 2014 Oct;3(3-4):405-16. doi: 10.1159/000343861. Review. PubMed PMID: 26280002; PubMed Central PMCID: PMC4531424.

3: Kudo M. Biomarkers and Personalized Sorafenib Therapy. Liver Cancer. 2014 Oct;3(3-4):399-404. doi: 10.1159/000343870. PubMed PMID: 26280001; PubMed Central PMCID: PMC4531426.

4: Erika G, Federica Z, Martina S, Anselmo P, Luigi R, Marina M, Davide C, Eleonora Z, Monica V, Silverio T. Old tyrosine kinase inhibitors and newcomers in gastrointestinal cancer treatment. Curr Cancer Drug Targets. 2015 Aug 17. [Epub ahead of print] PubMed PMID: 26278713.

5: Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y. Delivery of siRNA using CXCR4-Targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Anti-Tumor Response in Liver Cancer. Mol Ther. 2015 Aug 17. doi: 10.1038/mt.2015.147. [Epub ahead of print] PubMed PMID: 26278330.

6: Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2015 Jul 28. pii: S0022-4804(15)00807-0. doi: 10.1016/j.jss.2015.07.033. [Epub ahead of print] PubMed PMID: 26277218.

7: Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS One. 2015 Aug 14;10(8):e0134731. doi: 10.1371/journal.pone.0134731. eCollection 2015. PubMed PMID: 26275293.

8: Jiang E, Shangguan AJ, Chen S, Tang L, Zhao S, Yu Z. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Lett. 2015 Aug 10. pii: S0304-3835(15)00471-1. doi: 10.1016/j.canlet.2015.07.016. [Epub ahead of print] PubMed PMID: 26272181.

9: Sacco R, Antonucci M, Bargellini I, Marceglia S, Mismas V, Cabibbo G. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice? Future Oncol. 2015 Aug 13:1-3. [Epub ahead of print] PubMed PMID: 26270206.

10: Ch'ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol. 2015 Aug 8;7(16):2029-40. doi: 10.4254/wjh.v7.i16.2029. Review. PubMed PMID: 26261692; PubMed Central PMCID: PMC4528276.